Loading...
TrendSpott

TrendSpott

TrendSpott
 
 
Astrazeneca
61.05
-0.46%
 

AZN

61.05
-0.46%
Astrazeneca
 

 
Sentiment
 
TrendSpott
4.07
Buy
 
 

54.84

66.5

66.92

59.1

 
 
1m
3m
6m
1y
 

Summary

Astrazeneca (AZN) gets an overall score of 4.07 based on 70 events in the past 90 days from financial news and social media on a scale of 1 (strong sell) to 5 (strong buy). Last updated Nov 9, 2022 16:40
 

Rewards

TrendSpott

Upgraded on attractively valued

TrendSpott

Strong growth potential

 

Risk Analysis

TrendSpott

Enter oversold territory

 
 
Analysts Opinion
 
 
Earnings ×
 

Earnings

2.00
 
 
 
Rating ×
 

Rating

5.00
 

TrendSpott

Upgraded on attractively valued

 
Momentum ×
 

Momentum

2.75
 

TrendSpott

Has been gaining momentum

TrendSpott

Price value has negative momentum

TrendSpott

Enter oversold territory

 
Activity ×
 

Activity

3.75
 
 
Potential ×
 

Potential

4.00
 

TrendSpott

Strong growth potential

 
 

Analysts opinion is positive and also has improved from the past 3 months

 
Street Consensus
Buy
Opinion
Trend
Score
Potential
Score
 
79%
100%
38%
100%
 
On Track
On Track
On Track
 

 

Street view is extremely ish and have postive views on the near-term outlook

 
Key Metrics
Previous
Score
Current
Score
 
Potential
3.50

4.00
 
Rating
NA

5.00
 
Earnings
2.00

2.00
 
Momentum
4.00

2.75
 
Activity
3.55

3.75
 
Events Rating
 
Very Bullish
Bullish
Neutral
Bearish
Very Bearish
 
Positive vs Negative
 
79%
14%
Positive
Negative
55 out of 70
events present
10 out of 70
events present
 

 
Events Calendar
October
S
M
T
W
T
F
S
November
S
M
T
W
T
F
S
 
Highlights
Last
Modify
Closing
Price
%
Change
 
Buy Rating
3 Month Ago
65.83
-0.74%
 
Latest Events

options traders expect astrazeneca shares to fall after earnings report as stock is up 5% in 2022. on cnbc'.s &.options action&. ) traded 3.9 times its average daily put . the trade implied a move of about 3.6% in the stock by the end of the week whic

Benzinga - markets

Today

Momentum

astrazenecas inhaled asthma therapy gets fda panel nod for use in adults but not for kids.

Seeking Alpha Symbol - AZN

Today

Activity

astrazeneca : fda panel recommends approval of asthma treatment pt027 in adults but not for children. (rttnews) - the United States fdas pulmonary-allergy drugs advisory committee voted 16 to 1 in favor of approval of pt027 (albuterol/budesonide) for the

Nasdaq Symbol - AZN

Today

Activity

astrazenecas covid vaccine vaxzevria gets full approval in eu.

Seeking Alpha Symbol - AZN

Tue Nov 1, 2022

Activity

astrazenecas camizestrant improves survival vs faslodex in phase 2 breast cancer trial.

Seeking Alpha Symbol - AZN

Wed Oct 26, 2022

Activity

amgen astrazenecas severe asthma therapy tezspire launches in canada.

Seeking Alpha Symbol - AMGN

Wed Oct 26, 2022

Activity

astrazeneca: capivasertib phase iii trial meets primary goals. (rttnews) - british drug major astrazeneca plc (azn.l) wednesday announced positive high-level results from the capitello-291 phase iii trial of capivasertib in combination with faslodex (fulv

Nasdaq Symbol - AZN

Wed Oct 26, 2022

Activity

azn : camizestrant improves progression-free survival in phase ii trial in advanced breast cancer. (rttnews) - british drug major astrazeneca plc (azn.l) said that results from serena-2 phase ii trial showed that camizestrant provided a significant improv

Nasdaq Symbol - AZN

Wed Oct 26, 2022

Activity
Activity

astrazeneca: fasenra trial in eoe did not meet one of two dual-primary endpoints. (rttnews) - british drug major astrazeneca plc (azn.l) tuesday announced that messina phase iii trial for fasenra (benralizumab) failed to meet one of the two dual-primary e

Nasdaq Symbol - AZN

Tue Oct 25, 2022

Activity
Activity

astrazeneca drug fails one main goal in study of chronic immune disease. drugmaker astrazeneca said on tuesday that its asthma drug fasenra failed to meet one of two main goals of a late-stage study assessing the treatments benefits in a chronic allergic

Nasdaq Symbol - AZN

Tue Oct 25, 2022

Activity
Activity

astrazeneca inhaler breztri for lung disorder launched in canada.

Seeking Alpha Symbol - AZN

Mon Oct 24, 2022

Activity

astrazenecas imjudo/imfinzi combo for liver cancer gets fda approval.

Seeking Alpha Symbol - AZN

Mon Oct 24, 2022

Activity

astrazenecas imfinzi combo scores fda approval for liver cancer. the fda has approved) imjudo (tremelimumab) in combination with imfinzi (durvalumab) for unresectable hepatocellular carcinoma (hcc) the

Benzinga - news

Mon Oct 24, 2022

Activity

astrazeneca-oxford university partnered nasal covid-19 vaccine flunks human trial. ) and oxford university scientists said that the initial testing of its nasal covid-19 vaccine did not yield the desired protection. the astrazeneca-funded phase 1 trial

Benzinga - large-cap

Tue Oct 11, 2022

Momentum

astrazeneca pays 660% premium for gene therapy firm logicbio. shares of logicbio therapeutics skyrocketed on monday after britains astrazenecas said it would buy the United States-based gene therapy developer at a rare 660% premium for $68 million.

Nasdaq Symbol - AZN

Mon Oct 3, 2022

Momentum

logicbio to be bought by alexion astrazeneca rare disease. (rttnews) - logicbio therapeutics inc. (logc) a company focused on gene delivery and editing platforms to treat rare diseases said on monday that it has inked a deal to be acquired by alexion astr

Nasdaq Symbol - VTAQ

Mon Oct 3, 2022

Activity

nasdaq 100 movers: lcid azn. in early trading on thursday shares of astrazeneca topped the list of the days best performing components of the nasdaq 100 index trading down 0.3%. year to date astrazeneca has lost about 6.4% of its value.

Nasdaq - News

Thu Sep 29, 2022

Momentum

astrazenecas (azn) ultomiris gets ec nod for new indication. astrazeneca azn announced that the european commission has granted marketing approval to long-acting c5 complement inhibitor ultomiris for a new indication — myasthenia gravis (gmg) —

Nasdaq - Investing

Mon Sep 26, 2022

Activity

astrazeneca ultomiris gets approval in eu to treat rare neuromuscular disorder.

Seeking Alpha - AZN

Fri Sep 23, 2022

Activity

ionis stock dips as astrazeneca decides not to move cholesterol drug in phase 3 after mid-stage disappoints.

Seeking Alpha - AZN

Fri Sep 23, 2022

Momentum

astrazeneca announces approval for ultomiris by the european commission. (rttnews) - astrazeneca plc (azn.l azn) announced ultomiris has been approved in europe as an add-on to standard therapy for the treatment of adult patients with generalised myasthen

Nasdaq - AZN

Fri Sep 23, 2022

Activity

astrazeneca: tezspire gets eu approval to treat severe asthma. (rttnews) - british drug major astrazeneca plc (azn.l azn) wednesday said its tezspire (tezepelumab) has been approved in the european union for the treatment of severe asthma.

Nasdaq - AZN

Wed Sep 21, 2022

Activity

astrazenecas evusheld gets approval in eu to treat covid-19.

Seeking Alpha - AZN

Tue Sep 20, 2022

Activity

astrazenecas evusheld gets ema panel nod to treat certain covid-19 patients in eu.

Seeking Alpha - AZN

Fri Sep 16, 2022

Activity

astrazenecas danicopan shows benefit in rare blood disorder meets trials main goal.

Seeking Alpha - AZN

Fri Sep 16, 2022

Potential

astrazenecas evusheld gets chmp recommendation for eu approval to treat covid-19. (rttnews) - british drug major astrazeneca plc (azn.l azn) announced friday that its evusheld (tixagevimab and cilgavimab formerly azd7442) a long-acting antibody combinatio

Nasdaq - AZN

Fri Sep 16, 2022

Activity

astrazeneca beats United States shareholder lawsuit over covid vaccine disclosures. astrazeneca plc on monday won the dismissal of a United States shareholder lawsuit claiming that it concealed problems in developing its covid-19 vaccine making it unlikel

Nasdaq - AZN

Mon Sep 12, 2022

Activity

astrazeneca says lynparza combination shows meaningful os in ovarian cancer across phase iii trials. (rttnews) - british drug major astrazeneca plc (azn.l azn) announced friday positive long-term follow-up results from the paola-1 and solo-1 phase iii tri

Nasdaq - AZN

Fri Sep 9, 2022

Activity

ionis presents positive results from phase 3 study of eplontersen in neuropathy impairment. (rttnews) - ionis pharmaceuticals inc. (ions) presented positive results from a planned 35-week interim analysis of the phase 3 neuro-ttransform study of ionis and

Nasdaq - AZN

Wed Sep 7, 2022

Activity

astrazeneca imfinzi combo scores fda approval as first immunotherapy regimen for biliary tract cancer. the) imfinzi (durvalumab) for locally advanced or metastatic biliary tract

Benzinga - large-cap

Tue Sep 6, 2022

Activity

 
 
 
TrendSpott

Get all the pieces of the puzzle on important data activity before the major news sources break the story and find out what happening right now and what could happen in the future

FIND US ON

TrendSpott on Twitter TrendSpott on YouTube TrendSpott on stocktwits
 

Receive our daily AZN alerts

Enter your email to receive daily alerts

SECURITY POWERED BY

secure
guaranteed
 
Home

Leading Gainers

Upgrades

Downgrades

Top Leaders

 
Categories

Ipo's

Dividend

Option Activity

Insiders Activity

Institutional Holdings

 
Tags

New Products

FDA Approvals

Agreements

Financial Reports

 
About Us

Log In

Sign Up

Contact Us

Terms of use

Privacy Policy

 
 

Disclaimer: The Score performance whether actual or indicated by historical tests of strategies, is no guarantee of future performance or success. The results reflect performance of a strategy not historically offered to investors and does not represent returns that any investor actually attained. The results reflect performance of a strategy not historically offered to investors and does not represent returns that any investor actually attained. The Readiness Indicators, Sentiment Indicators and total score are calculated by the retroactive application of a model constructed on the basis of historical data and based on assumptions integral to the model which may or may not be testable and are subject to losses. Active trading is generally not appropriate for someone of limited resources, limited invesment or trading experience, or low-risk tolerance. Your capital may be at risk.

Please note that no offer or solicitation to buy or sell securities, securities derivatives of future products of any kind, or any type of trading or invesment advise, recommendation or strategy, is made, given or endorsed by TrendSpott including any of their affiliates ("TS").

This information is provided for illustrative purposes only. You should not rely on any advice and/or information contained in this website and before making any investment decision. we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice.

 
TrendSpott

TrendSpott

Get the pulse of the market

 
TrendSpott

TrendSpott BETA

AZN
Astrazeneca
61.05
-0.46%
 
 
 

Recently Viewed

 

AZN

Astrazeneca

 
 
 

Most Trending

 
 
 

Summary

Astrazeneca (AZN) gets an overall score of 4.07 based on 70 events in the past 90 days from financial news and social media on a scale of 1 (strong sell) to 5 (strong buy). Last updated Nov 9, 2022 16:40

 
 
54.84
66.5
66.92
59.1
 
 
1m
3m
6m
1y
 

Rewards

TrendSpott

Upgraded on attractively valued

TrendSpott

Strong growth potential

Risk Analysis

TrendSpott

Enter oversold territory

 
Sentiment
 
TrendSpott
Total score
4.07
Buy
 
 
Street Consensus
 
Buy
Opinion
Trend
Score
Potential
Score
 
100%
38%
100%
On Track
On Track
On Track
 
79%
14%
Positive
Negative
55 out of 70
events present
10 out of 70
events present
 

Street view is extremely ish and have postive views on the near-term outlook

 
 
Analysts Opinion
 
 
Earnings ×
 

Earnings

2.00
 
 
 
Rating ×
 

Rating

5.00
 

TrendSpott

Upgraded on attractively valued

 
Momentum ×
 

Momentum

2.75
 

TrendSpott

Has been gaining momentum

TrendSpott

Price value has negative momentum

TrendSpott

Enter oversold territory

 
Activity ×
 

Activity

3.75
 
 
Potential ×
 

Potential

4.00
 

TrendSpott

Strong growth potential

 
 

Analysts opinion is positive and also has improved from the past 3 months

 
 
 
Events Rating
 
Very Bullish
Bullish
Neutral
Bearish
Very Bearish
 
 
Events Calendar
 
October
S
M
T
W
T
F
S
 
 
 
November
S
M
T
W
T
F
S
 
 
 
Highlights
Last
Modify
Closing
Price
%
Change
 
Buy Rating
3 Month Ago
65.83
-0.74%
 
 
 
TrendSpott

Get all the pieces of the puzzle on important data activity before the major news sources break the story and find out what happening right now and what could happen in the future

FIND US ON

TrendSpott on Twitter TrendSpott on YouTube TrendSpott on stocktwits

 

Receive our daily AZN Alerts

Enter your email to receive daily alerts

 

SECURITY POWERED BY

TrendSpott
TrendSpott
 
Home

Leading Gainers

Upgrades

Downgrades

Top Leaders

Categories

Ipo's

Dividend

Option Activity

Insiders Activity

Institutional Holdings

Tags

New Products

FDA Approvals

Agreements

Financial Reports

 
 

Disclaimer: The Score performance whether actual or indicated by historical tests of strategies, is no guarantee of future performance or success. The results reflect performance of a strategy not historically offered to investors and does not represent returns that any investor actually attained. The results reflect performance of a strategy not historically offered to investors and does not represent returns that any investor actually attained. The Readiness Indicators, Sentiment Indicators and total score are calculated by the retroactive application of a model constructed on the basis of historical data and based on assumptions integral to the model which may or may not be testable and are subject to losses. Active trading is generally not appropriate for someone of limited resources, limited invesment or trading experience, or low-risk tolerance. Your capital may be at risk.

Please note that no offer or solicitation to buy or sell securities, securities derivatives of future products of any kind, or any type of trading or invesment advise, recommendation or strategy, is made, given or endorsed by TrendSpott including any of their affiliates ("TS").

This information is provided for illustrative purposes only. You should not rely on any advice and/or information contained in this website and before making any investment decision. we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice.

 
 
 
 
 

Top Headlines